相关实验视频

Updated: Jan 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

类药物的副作用是否取决于性别? 一个叙事审查

Anna Braszak-Cymerman¹, Małgorzata Moszak², Wiesław Bryl¹

¹Department of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Poland.

Przeglad menopauzalny = Menopause review

|October 20, 2025

概括

女性对他类药物治疗的坚持程度低于男性,主要是由于他类药物的副作用和不耐受性. 了解这些性别特异性不良事件对于改善女性心血管风险管理至关重要.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
医学中的性别研究.

背景情况:

失脂症是心血管疾病 (CVD) 的关键可修改风险因素.
类药物是失脂症的主要治疗方法,但坚持是个重大挑战.
停止使用他类药物经常与不良反应和不耐受性有关.

研究的目的:

审查和讨论与男性相比,女性对他类药物的坚持程度较低.
评估性别与他类药物的副作用发生率之间的关联.
探索影响他类药物不耐受和坚持的性别特异因素.

主要方法:

从PubMed和Scopus数据库中对文章进行叙事审查.
搜索术语侧重于他类药物的坚持,不良事件和性别差异.
综合现有关于性别特异性他类药物结果的文献.

主要成果:

女性对他类药物治疗的坚持程度低于男性.
类固醇药物的不良反应和不耐受性是不良坚持的主要驱动因素.
由于副作用,女性更容易停止服用他类药物,并认为它们的安全性/有效性较低.
女性性别是他类药物不耐受的一个危险因素,他类药物相关肌肉症状 (SAMS) 和新发糖尿病的患病率更高.
女性更容易受到与他类药物相关的nocebo和drucebo效应.

结论:

性别显著影响了他类药物的坚持和副作用的经历.
对性别特异性他类药物的副作用的认识可以指导个性化治疗.
对女性进行改进,量身定制的他类药物治疗可能会增强坚持并降低心血管风险.

关键词:

脱脂血症是什么脱脂血症性别差异的性别差异.关于他类药物的坚持类他类药物的副作用类药物类药物类药物

更多相关视频

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways

Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways

Published on: December 9, 2013

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...